Leishmaniasis is caused by protozoans of genus Leishmania that involves several species. This zoonosis is considered the sixth disease of greater importance by World Health Organization (WHO). Several works have demonstrated that L. amazonensis is able to produce a large spectrum of lesions in mice´s liver, spleen, bone marrow and brain. The treatment of leishmaniasis is not satisfactory. The pentavalent antimony is toxic and has to be used for prolonged periods, causing adverse effects. Concanavalin-A (Con-A) is a lectin derived from the seeds of jack beans (Canavalia ensiformis), that stimulates immune system, activating macrophages. Studies have associated this lectin with a protection role in the liver upon fungal and bacterial infections. However, the effect in experimental infection with Leishmania species is not clear. Thus, we investigated if Con-A plays a protector role in BALB/c mice pretreated and infected with L. amazonensis. Five animals per group were pretreated with Con-A or PBS for 72h intraperitoneally and infected with 10⁷ promastigotes forms for 15 days. The non-treated and infected mice were used as a control. The supernatants obtained from intraperitoneal exsudate were used to determine the levels of IL-1β at 30 minutes post infection in others 3 animals per group. After 15 days, the liver of each animal was removed, perfused and sectioned into standardized fragments. The tissue was processed for paraffin embedding, sectioned (6μm) and stained with hematoxylineosin (H&E). Cellular infiltrate scored by counting the number of cells in infiltration, absolute number of infiltration area, presence of alterations in the total area were performed. We observed that the levels of IL-1β in PBS group were larger at 30 min than Con-A group. The pretreatment with Con-A (7,6 ± 2,50) leads to lower number of infiltrates when compared with PBS group (10,2 ± 1,78) and absolute number of cells per infiltrate area. We observed the presence of pyknotic nucleus and loss of hepatocyte membrane in PBS group. Our model suggests a protector role of Con-A on the liver in experimental leishmaniasis, with lower IL-1β production (it is produced in response to inflammatory agents, infections); and a lower number of cell in infiltrates. Concanavalin-A is not used in therapy but permit us understanding the parasite-host relation to promote future studies.